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A Schistosomiasis Research Agenda
As relatively new schistosomiasis researchers, we awaited with
eagerness the publication of the ‘‘Schistosomiasis Research
Agenda’’ (SRA) put forward by Colley and Secor in the December
2007 issue of PLoS Neglected Tropical Diseases [1]. The SRA is a
comprehensive, well-organized list of research activities that
reflects the impressive diversity of interests that make up current
schistosomiasis research. Colley and Secor went to admirable
lengths to solicit the interests of researchers the world over, with
special efforts to solicit the opinions of scientists in countries or
regions where schistosomiasis is endemic, such as Brazil, China,
and Africa. Having attended some of these meetings (11th
International Congress of Parasitology, held in Glasgow, United
Kingdom in August 2006; and the 55th Annual Meeting of the
American Society of Tropical Medicine and Hygiene, held in
Atlanta, United States in November 2006) and received the e-
mails, we are confident that the SRA indeed reflects the richness
and breadth of current schistosomiasis research.
As noted by Colley and Secor [1], many of these areas of
interest in the SRA are applicable to the study of almost any
neglected tropical disease (NTD). However, while research into
other tropical diseases such as malaria and a number of the
NTDs—most notably hookworm disease, cysticercosis, and
leishmaniasis—are currently enjoying a ‘‘renaissance’’, with
increased funding from major philanthropies such as the Bill
and Melinda Gates Foundation [2], research into schistosomiasis
remains one of the truly neglected areas of NTDs. This problem
exists despite the fact that schistosomiasis is arguably the most
important human helminth infection in terms of global morbidity
and mortality as measured by disability-adjusted life-years
(DALYs). Recently, King et al. [3] revised upwardly the DALY
estimates for schistosomiasis, by including not only gross organ
pathology as a disability, but also the anemia, pain, diarrhea,
exercise intolerance, and under-nutrition that result from chronic
infection with schistosomes. In 2003, the Gates Foundation
provided a grant of US$30 million to create the Schistosomiasis
Control Initiative (SCI), an organization that facilitates mass
administration of praziquantel (PZQ) currently in six African
countries [4]. The use of PZQ as a safe, inexpensive, and
efficacious method to resolve current schistosomiasis infection and
morbidity is admirable; however, there has developed an
unexpected, yet serious, long-term side effect—the spurious
perception that widespread use of PZQ makes schistosomiasis a
problem of the past [5]. This misconception has promoted the
belief amongst some funding bodies that we already have all the
requisite tools to control schistosomiasis (i.e., PZQ), and
development of new control strategies is unnecessary. Given the
extensive burden of disease related to schistosomiasis, relying solely
on mass and repeated treatment of exposed populations with PZQ
is not enough to sufficiently control, let alone eradicate, this disease
[6,7].
Diversity versus Divisiveness
As noted by Colley and Secor [1], the diversity of backgrounds
and interests in schistosomiasis, while enriching the field, may have
also led to a ‘‘divisiveness’’ that has harmed its progress. In our
opinion, there has been no greater area of divisiveness in
schistosomiasis research than the debate on the use of chemo-
therapy versus vaccines for controlling schistosomiasis [8–12]. The
debate did not result in a ‘‘fruitful reorientation of schistosomiasis
research’’ as proferred [8], but has solidified researchers into the
simplistic camps of ‘‘for’’ and ‘‘against’’ vaccines [7]. Furthermore,
although we agree that there is much diversity in the field of
schistosomiasis research, we do not feel that this diversity is
inherently harmful. Perhaps even more troubling is the chronic
discord within disciplines, whether it is epidemiology, immunol-
ogy, genomics, proteomics, or control.
A Way Forward
Rather than commenting on the exhaustive list of interests
spanned and the numerous combinations of research interests and
disciplines possible, we have instead chosen to discuss mechanisms
by which the diverse interests of the SRA might be integrated into
a potential way forward for the field. We feel that this is best
accomplished by looking outside of schistosomiasis to fields in
which similar diversities—but not divisiveness—exist and re-
searchers work harmoniously and productively. Box 1 highlights
some examples of networks that are considered to be highly
successful by many of their respective members. For instance,
malaria research is a large and highly competitive field, but a
number of networks and foundations exist to foster collaboration,
communication, and interactions amongst members. This is best
exemplified by BioMalPar, which has been a great success for the
malaria community and laboratories in both Europe and endemic
countries. Many consider the flagship of BioMalPar to be its PhD
program, which is centered on joint supervision of doctoral
students and genuine time spent in multiple laboratories in
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openness amongst malaria groups (many of which were tradition-
ally rivals) are considered to be truly impressive by malariologists.
We have interacted with the other two networks listed in Box 1,
which we believe are equally successive at bringing researchers
together.
Why Do These Networks Work?
The successful networks highlighted above have one thing in
common: they are well funded. However, this was not always the
case—these researchers had to come together, agree on a granting
agency to target, and develop a suitable agenda by which to solicit
funding. We suggest that the SRA is the place to start a similar
effort for schistosomiasis with the following objectives: (a) fostering
interdisciplinary methods; (b) standardizing research protocols; (c)
elevating the profile of schistosomiasis within the global health
community; (d) creating repositories of biomaterial; and (e)
utilizing expertise outside of schistosomiasis. An example of a
well-funded cooperation within schistosomiasis already exists. The
Biomedical Research Institute (BRI) in Maryland, US is a facility
that supports schistosomiasis research through the provision of
parasite material and a repository for reagents. The BRI
schistosomiasis program is funded by National Institutes of Health,
highlighting to the community that granting bodies are prepared
to fund schistosomiasis research and nurture collaborative efforts.
A Start
We need to build upon the momentum created by the SRA. As
a start, we should not consider the SRA as a static document, nor
the end of a process, but the start of one. Indeed, one of the best
aspects of the SRA was the transparent manner in which it was
created and composed, which involved an extensive emailing list,
frank conversations between researchers, lively meetings of the
schistosomiasis community at major conferences, and the
understanding that the SRA would not promote any one group
of researchers or area of research, but was a voice for the entire
community. With this infrastructure already in place, we should
come together in an effort to secure funding that does not directly
benefit any one of our research programs, but further unifies the
community, accelerating its ‘‘recovery’’ to that warranted by the
severity of the disease itself.
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Box 1. Some Models of Interdisciplinary
Research Networks
1. BioMalPar – ‘‘Biology and Pathology of Malaria Parasite’’
is a Network of excellence funded by the European
Commission. Thirty-two leading institutes from 10
European and 6 developing countries involved in
fundamental research coordinate their efforts in a virtual,
multi-center ‘‘European Malaria Research Institute’’. Many
consider their flagship to be a PhD program that
supports collaborative research projects between two
or more institutions. http://www.biomalpar.org/
2. ARC/NHMRC Parasitology Research Network – Australian
government funded network to promote collaborations
between Australian and international researchers. Fund-
ing for collaborative travel and grant writing retreats and
an annual conference are provided by the network.
http://parasite.org.au/arcnet/
3. Consortium for Functional Glycomics – a large research
initiative, funded by the National Institutes of Health
(NIH), and formed to define the paradigms by which
protein-carbohydrate interactions mediate cell commu-
nication. The strategy is to work with the scientific
community to create unique resources and services
that participating investigators can utilize in their own
research. http://www.functionalglycomics.org/static/
index.shtml
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